This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies Part 1 of the study is monotherapy dose escalation.
SparkCures ID | 912 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 70 Patients |
Treatments | |
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Inclusion criteria for expansion cohorts in CLL and MM (Part 2 only):
Inclusion for AZD5991+venetoclax:
Exclusion Criteria:
Exclusion AZD5991 + venetoclax
Please visit the ClinicalTrials.gov page for historical site information.
View Centers